[Insulin therapy in type 2 diabetes. Insured patients would be willing to pay for added benefits].
D002675:Child, Preschool; D003362:Cost-Benefit Analysis; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000191:economics*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000191:economics*; D005382:Financing, Personal / Q000191:economics*; D005858:Germany; D006801:Humans; D007328:Insulin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D000069057:Insulin Detemir; D049528:Insulin, Long-Acting; D007356:Insurance, Pharmaceutical Services / Q000191:economics; D009313:National Health Programs / Q000191:economics*
D007328:Insulin; D049528:Insulin, Long-Acting; D000069057:Insulin Detemir